ResVax RSV Vaccine Description
ResVax is an aluminum adjuvanted RSV fusion (F) protein recombinant nanoparticle vaccine.
ResVax RSV Vaccine Indication
ResVax is indicated to prevent severe RSV disease, protecting infants as early as birth and during the first months of life when they are most at risk for hospitalization.
ResVax is administered to the maternal participant as an intramuscular (IM) Injection of RSV F Vaccine at 28-36 weeks Estimated Gestational Age (EGA).
ResVax RSV Vaccine News
July 21, 2021 - ResVax narrowly missed its primary efficacy endpoint in the pivotal PREPARE study, and while it hit key secondary endpoints, the EMA and FDA have requested an additional confirmatory efficacy study before considering approval. The elderly segment offers the most commercial potential because of the large population size, high coverage rates that can be achieved, and the likely requirement for repeat seasonal vaccination. ResVax also failed to meet its primary efficacy endpoint in this subgroup in the RESOLVE study,
August 12, 2019 - Novavax presented new data from Novavax Phase 3 Prepare Trial of ResVax Presented at 2019 IDSOG Annual Meeting
June 10, 2019 - Novavax Provides Updates on the Global Pathways to Licensure for ResVax™
February 28, 2019 - Novavax Announces Topline Results from Phase 3 PrepareTM Trial of ResVax™ for Prevention of RSV Disease in Infants via Maternal Immunization
ResVax RSV Vaccine Clinical Trials
ResVax RSV vaccine has completed 4 clinical trials to date.